Biotech & Research

The bill establishes the National Biotechnology Initiative to advance biotechnology through coordination, R&D support, regulatory streamlining, commercialization, workforce development, and other activities across multiple federal agencies (Sections 3-6). This provides clear benefits to the biotech industry via federal support, reduced regulatory barriers, and increased commercialization opportunities.

Section 2(b)(1) directs measurement research to support development and improvement of best practices and technical standards for biosecurity measures related to nucleic acid synthesis, which benefits biotech firms engaged in synthetic nucleic acid procurement and screening.

Section 2(b)(1) authorizes high-risk, high-reward research on trisomy 21 effects, which benefits biotech firms engaged in genetic and biomedical research.

Section 6 amends the Hunter Kelly Research Program to require entities receiving funding to work in consultation with State departments of health, which benefits biotech firms engaged in newborn screening research and technology development.

The bill extends SBIR and STTR programs through fiscal year 2026, which provide federal funding for small business innovation research and technology transfer, directly benefiting biotech firms engaged in R&D.

Section 2 reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, increasing appropriations from $31,009,000 to $33,009,000 for FY 2027-2031, providing a clear benefit to biotech and research firms involved in stem cell therapeutics.

Section 2(b)(1) directs development of a network of commercial facilities for biomanufacture of defense-critical products; Section 2(b)(2) calls for updating military specs to incorporate biotech products; Section 2(b)(3) includes advance market commitments and offtake agreements for biotech products; Section 2(b)(5) proposes research grand challenges to make biotech predictably engineerable; Section 2(b)(6) calls for a biotech regulation science and technology program; Section 2(b)(7) and (8) i

Section 2 requires a fair percentage of Federal cancer research funds to be dedicated to pediatric cancer research, which will increase funding for biotech and research firms engaged in pediatric cancer research, such as Moderna, Regeneron, Vertex, and gene-therapy startups.

Section 3(a)(2)(C) and (D) focus on advancing workforce training and deploying infrastructure for innovative biopharmaceutical manufacturing by engaging with institutions of higher education, pharmaceutical manufacturers, and other entities, which supports biotech research firms and life-sciences companies involved in biopharmaceutical development.

Section 2(c) authorizes NIH to award grants or contracts to carry out the IMPROVE Initiative, which will fund research on maternal health. This benefits biotech firms engaged in NIH‑aligned research and development.

Section 2(b)(6) evaluates opportunities for expanded NATO capabilities to research, develop, and deploy biotechnology for international security purposes; Section 2(c)(1) explores potential areas of cooperation with major non-NATO allies in biotechnology; Section 2(d)(2)(A) proposes commitments or agreements to expand cooperation on international security matters relating to biotechnology; Section 2(d)(2)(B) assesses feasibility of coordinating export control efforts related to biotechnology ite

Section 2(c)(1) and Section 3(e)(1)(B)(iii) authorize grants for research on neurorehabilitation treatments, clinical studies, and randomized controlled trials for TBI treatments, which could benefit biotech firms developing novel therapies or diagnostics.

Section 2(b)(4) requires manufacturers of investigational drugs to share interim clinical trial data with the Secretary, facilitating ALS therapy research and benefiting biotech firms developing such therapies.

The bill covers biosimilars (referenced in Section 2(a)(2) via section 351(k) of the Public Health Service Act), and deterring sham petitions facilitates biosimilar approval, benefiting biotech firms developing biosimilar products.

The bill authorizes grants for forensic genetic genealogical DNA analysis and searching, which involves whole genome sequencing and use of genetic genealogy services, directly benefiting biotech firms involved in genetic testing, sequencing, and database services (e.g., companies like 23andMe, Ancestry, or specialized forensic genomics providers). Sections 3062(b), (d), (e), and 3063(b), (d) authorize funding for technology and services that align with biotech industry activities.

Section 3 focuses on biopharmaceutical manufacturing, which is a core activity of biotech firms; the center will support collaborative research, technology scaling, and workforce training for the biotechnology sector, providing clear benefits.

Section 3 creates a strategic breakthrough allocation for SBIR/STTR awards up to $30M for small businesses, including those in biotech, with eligibility criteria favoring technologies advancing national security and market readiness, providing clear benefit via funding and streamlined contracting.

Section 2(f)(3) authorizes translational research on growth hormone replacement therapy for cognitive function, which could benefit biotech firms developing such therapies.

Biotech firms often manufacture specialty drugs; Section 2(c)(1) specifies the amendments apply to standards for specialty drugs, meaning financial assistance for high-cost biologics and gene therapies will count toward out-of-pocket limits, improving patient access and supporting biotech sales.

Resolution highlights FDA's Accelerating Rare disease Cures Program and notes 26 of 50 novel drugs approved in 2024 were for rare diseases, indicating support for biotech research and development.

Section 5(b) amends Section 3205 of the Food and Drug Omnibus Reform Act of 2022 to update best practices on generating scientific data necessary to facilitate development of certain human cell-, tissue-, and cellular-based medical products, namely stem cell and other cellular therapies. This directly benefits biotech firms developing such therapies by streamlining regulatory pathways and providing updated scientific guidance.

Section 3's special provisions for practitioners conducting research with Schedule I substances, including expedited procedures and transparency requirements, facilitate research on fentanyl-related substances, benefiting biotech firms involved in opioid-related drug development.

Section 2(a)(1)(A) and (B) mandate updating regulations to replace animal test references with nonclinical test definitions, which benefits biotech firms engaged in drug development by enabling use of innovative non-animal testing approaches.

Section 1(a)(2) supports increased capacity to identify, report, prevent, and respond to vector-borne diseases, which can benefit biotech firms involved in diagnostics, vaccines, and therapeutics for diseases like Lyme and other tick-borne illnesses.

Section 2(a)(2) defines covered tests to include genomic sequencing, whole exome, whole transcriptome, and protein expression analyses, which are biotechnology-based diagnostic tests. Medicare coverage would increase demand for biotech firms developing and manufacturing these screening tests.

Expanded Medicare coverage for genetic counseling services increases demand for genetic testing and counseling, which benefits biotech firms involved in genetic testing, diagnostics, and related research (e.g., Moderna, Regeneron, Vertex).

Section 2(a)(2)(A)(iii) adds lung cancer biomarker testing to Medicaid coverage, which will increase utilization of biomarker assays and related biotech products used in cancer diagnostics.

Section 2(a)(2)(B) mandates Medicare coverage of lung cancer biomarker testing, which will drive utilization of biomarker assays developed by biotech firms (e.g., gene or protein-based tests), expanding their market.

Section 5(b)(1)(A) prohibits MA organizations from applying medical necessity criteria more restrictive than Original Medicare's reasonable and necessary standards under section 1862(a)(1), which could improve coverage for innovative biotech therapies and gene treatments that often face prior authorization hurdles.

The bill defines multi-cancer early detection screening tests as genomic sequencing blood tests analyzing cell-free nucleic acids (Section 2(a)(2)(nnn)(1)(B)(i)), a technology primarily developed by biotech firms. Medicare coverage (Section 2(a)(1)(B)) creates a market for these tests, directly benefiting biotech companies involved in cancer diagnostics (e.g., Illumina, GRAIL, Roche).

Title II provides $6.6B for NIAID (allergy/infectious diseases), $4.5B for NIA (aging), and $1.5B for ARPA-H, all of which fund biotech research and development; Sec. 214 allows NIH to use funds for transactions related to research activities.

The task force focuses on patents for human drugs and biological products, which includes biologics developed by biotech firms; improved coordination may reduce patent prosecution delays and benefit biotech innovation.

Section 3 directs NIH to conduct a study on mental health disparities research gaps, which could benefit biotech firms involved in mental health research and development, particularly those aligned with NIH grants.

Sections 602, 603, 604, 606 directly address biotechnology talent, genomic data security, synthetic DNA/RNA procurement, and outbound investment screening for biotech, clearly benefiting the biotech industry.

Section 2(e)(1)(B)(i) includes National Drug Code and other identifiers that apply to biologics and gene therapies; Section 3(f)(2)(A) extends this to clinical diagnostic lab tests, which often involve biotech-developed assays, thereby increasing transparency for biotech products and potentially aiding market adoption.

Title II includes $6,592,279,000 for National Institute of Allergy and Infectious Diseases and $1,500,000,000 for Advanced Research Projects Agency for Health, which fund biotech research and vaccine development.

Section 2 includes provisions for considering breakthrough therapies (Section 2(c)(4)(A)) and vaccines for public health emergencies (Section 2(c)(4)(B)), which benefits biotech firms developing novel vaccines and immunotherapies by facilitating faster review and recommendation processes.

Section 3(a)(9) specifically mentions supporting scalable biotechnology experimentation as a transformative result of the network, indicating direct benefit to biotech research and development.

Section 2(a)(1)(A) amends regulations to replace animal test references with nonclinical tests, which benefits biotech firms engaged in drug development by enabling use of innovative non-animal testing approaches.

Resolution highlights advancements in mRNA technology and global vaccine deployment as public health progress, directly benefiting biotech firms involved in vaccine and therapeutic development.

The SOAR program includes health and wellness training that may involve biotech-related health interventions or research, indirectly supporting biotech firms through public health training initiatives.

Section 2(c)(4) includes genetic testing of embryos, which will increase demand for biotech products and services related to preimplantation genetic testing.